Zentalis Pharmaceuticals Inc's fundamentals are relatively very weak, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 152 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.80.In the medium term, the stock price is expected to trend up.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Zentalis Pharmaceuticals Inc is 3.95, ranking 390 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Key Metrics
The current valuation score of Zentalis Pharmaceuticals Inc is 7.54, ranking 106 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.15, which is -71.23% below the recent high of -0.33 and -517.28% above the recent low of -7.09.
The current earnings forecast score of Zentalis Pharmaceuticals Inc is 7.33, ranking 294 out of 392 in the Biotechnology & Medical Research industry. The average price target is 4.50, with a high of 10.00 and a low of 2.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Zentalis Pharmaceuticals Inc is 5.69, ranking 300 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.50 and the support level at 1.72, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Zentalis Pharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 90.22%, representing a quarter-over-quarter increase of 52.39%. The largest institutional shareholder is The Vanguard, holding a total of 2.86M shares, representing 3.95% of shares outstanding, with 12.95% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Zentalis Pharmaceuticals Inc is 2.23, ranking 245 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.73. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Zentalis Pharmaceuticals Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.
